Hematologic Disorder
8
1
2
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
12.5%
1 terminated out of 8 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Prophylaxis of Hematologic Complications With Naderin in First-Line Breast Cancer Chemotherapy
Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
Dexamethasone Dyspnea Study
Ovarian Tissue Freezing For Fertility Preservation In Women Facing A Fertility Threatening Medical Diagnosis/Treatment
Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)
Fertility Preservation With Ovarian Tissue Freezing